Precision for Medicine

Precision for Medicine is a clinical research organization focused on precision medicine, providing specialized services to pharmaceutical and life sciences companies. The organization supports the development and commercialization of new products by offering an integrated infrastructure that includes laboratory expertise, advanced data science, and clinical trial capabilities. With a strong emphasis on biomarkers, Precision for Medicine helps clients optimize patient treatments through precise targeting. The company leverages a state-of-the-art biorepository and laboratory, along with capabilities in biomarker identification and companion diagnostic product development. By assembling a diverse team of scientists, clinical trial experts, and technical specialists, Precision for Medicine enables its clients to navigate the complexities of modern medical research while adhering to evolving regulatory requirements.

Chad Clark

COO

Mark P. Clein

Co-Founder and CEO

Karl Deonanan

CFO

Christopher Ellis

Regional Vice President, Strategic Alliances, North America

Doug Fulling

President, Precision AQ

Ethan D. Leder

Founder

Jon Schwinn

Vice President, Corporate Development

7 past transactions

Algorics

Acquisition in 2024
Algorics Inc specializes in developing clinical analytics solutions and software tailored for the life sciences industry on a global scale. The company offers a suite of products, including a regulatory compliant cloud-based platform called Acuity, which enables users to convert data into actionable insights for evaluating drugs and diseases. Additionally, Algorics provides Acuity RBM, a tool that facilitates collaboration among teams to identify risks and formulate mitigation strategies transparently, and Acuity Insights, which aims to minimize regulatory risks while enhancing quality and compliance through real-time insights. Founded in 1980 and based in Houston, Texas, with an office in Piscataway, New Jersey, Algorics operates as a subsidiary of OmniComm Systems, Inc. The company's solutions assist bio-pharma companies and contract research organizations in conducting more efficient clinical trials by leveraging real-time clinical data insights.

Project Farma

Acquisition in 2021
Project Farma is a consulting firm of healthcare companies across the complete supply chain pharmaceutical,medical device manufacturers.

ProMedDx

Acquisition in 2019
ProMedDx is a contract research company that specializes in providing human biologics and supporting clinical services. The company offers a range of services, including annotated biospecimens, patient recruitment, prospective specimen collection, biospecimen procurement, bioprocessing, biostorage, and clinical study monitoring. These services are designed to support the biobanking industry by facilitating global biospecimen management and enhancing direct connections with patients.

Stern Investor Relations

Acquisition in 2018
Stern Investor Relations is an investor relations firm for entrepreneurial biotechnology and healthcare companies. We have comprehensive, up-to-the-minute knowledge of the technical, regulatory and financial aspects of this very dynamic industry. We closely monitor industry trends to provide a comprehensive, data-driven approach to investor relations counsel.

ApoCell

Acquisition in 2018
ApoCell, Inc. is a specialty clinical research company that specializes in the identification and analysis of biomarkers in rare circulating cells. The company provides a range of clinical trial support services across therapeutic areas, including oncology, inflammation, diabetes, and chronic kidney disease. Its offerings include sample logistics, project management, biomarker consultation, and companion diagnostics. ApoCell utilizes advanced liquid biopsy technology to detect and isolate circulating tumor cells and other rare cells from whole blood, providing less invasive diagnostic options compared to traditional tumor biopsies. The company also engages in customized biomarker assay development, encompassing proof-of-concept studies, validation of biomarkers, and support for good clinical practice and good laboratory practice studies. ApoCell serves pharmaceutical and biotechnology companies, as well as academic institutions, and has been involved in over 75 clinical studies addressing various cancers. Founded in 2004 and headquartered in Houston, Texas, ApoCell operates additional facilities in Leipzig, Germany, and is a subsidiary of Precision for Medicine, Inc.

Epiontis

Acquisition in 2017
Epiontis was founded in 2003 by Dr. Sven Olek and Dr. Ulrich Hoffmueller. The company is headquartered in the Science- and Technology Park Adlershof in the south of Berlin, Germany - a leading site for Biotechnology and Life Sciences in Berlin-Brandenburg. Epiontis offers worldwide services. Using a novel molecular diagnostics technology, Epiontis offers an immune cell monitoring service as well as customized development of epigenetic assays. Epiontis' epigenetic assay format allows the identification and quantification of any cell type with accuracy and technical ease. The main field of use is the monitoring of immune cells in research and clinical studies for autoimmune and infectious diseases or cancer. Here, they offer a portfolio of established assays for immune cells. Examples include diagnostic assays for regulatory T cells (Tregs) and tumor infiltrating lymphocytes, with many other epigenetic assays under development. In addition, they develop customized immunmonitoring essays that serve your needs.

Applied Immunology

Acquisition in 2016
Applied Immunology is a company that offers contract research laboratory services aimed at supporting the development of biological therapeutics and diagnostics. It specializes in cell-based assays and bioanalytical assays, which are essential for the evaluation of biologics. Additionally, the company focuses on clinical immune monitoring of products, providing valuable insights that assist in the therapeutic development process. Through its services, Applied Immunology plays a critical role in advancing the efficacy and safety of new medical treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.